Results 201 to 210 of about 23,280 (257)

SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes. [PDF]

Front Endocrinol (Lausanne)
Fang X, Li R, Liu S, Zou X, Zhong Y, Yang Y.   +5 more
europepmc   +1 more source

Beyond glycemic control: differential effects of empagliflozin and sitagliptin on insulin sensitivity and a shared increase in adropin in type 2 diabetes. [PDF]

BMC Endocr Disord
Taha OS, Azami G, Saed L, Hakhamaneshi MS, Moridi H.   +4 more
europepmc   +1 more source

Multi-Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial. [PDF]

Diabetes Obes Metab
Lim RP, Qassin S, McKenna L, Hornsey E, Italiano D, Churilov L, MacIsaac RJ, Seah JM, Ekinci EI, Austin EMPA‐MRI Study Group.   +9 more
europepmc   +1 more source

Green ratio-manipulating spectrophotometric methods for simultaneous determination of empagliflozin and sitagliptin in pharmaceutical formulations. [PDF]

BMC Chem
Mohamad AAA, Almrasy AA, Abdelazim AH, Taha AS.   +3 more
europepmc   +1 more source

The SGLT2i "canagliflozin" and the DPP-4i "sitagliptin" mitigate hypertensive nephropathy in adult male rats by modulating the Ang II/RAGE/Nox4/NLRP3 cascade. [PDF]

Front Physiol
Hassan FE, Al-Shahed FAN, Selmy A, Mahmoud LM, Aldreny BA.   +4 more
europepmc   +1 more source

Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study. [PDF]

Cureus
Chawla R, T K S, Singh KP, Mehta A, Chattopadhyay M, Rakshit KM, Motiramani N, Philip R, Shinde AC, K SM, Revenkar S, Patel K.   +11 more
europepmc   +1 more source

Comment on 'Renoprotective effects of dapagliflozin in diabetic patients with chronic kidney disease: A retrospective observational study'. [PDF]

Br J Clin Pharmacol
Chen J, Li Y.
europepmc   +1 more source

Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. [PDF]

Sci Rep
Mohamad AAA, Almrasy AA, Abdelazim AH, Taha AS.   +3 more
europepmc   +1 more source

Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Malik AF, Kashish F, Shivani F, Kumar S, Kumari V, Haseeb A, Mujtaba A, Raheem A, Ali SMS, Saleh U, Ahmad TKF.   +10 more
europepmc   +1 more source

Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study. [PDF]

Front Neurol
Chmiela T, Dulski J, Heckman MG, Fang ZJ, Wszolek ZK, Wilson JR.   +5 more
europepmc   +1 more source